Impact of age on outcomes of Japanese patients with rheumatoid arthritis treated with infliximab: The post marketing surveillance trial.

被引：0
|
作者：
Dabbous, O.
Rahman, M. I.
Gilmer, K.
Yano, T.
Nogami, Y.
Arjunji, R.
Thompson, H.
Tang, B.
Takeuchi, T.
Koike, T.
机构：
[1] Tanabe Seiyaku Co Ltd, Osaka, Japan
[2] Saitama Med Ctr, Kawagoe, Saitama, Japan
[3] Hokkaido Univ, Sapporo, Hokkaido, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S421 / S421
页数：1
相关论文
共 50 条
  • [41] Results of a German post-marketing surveillance study to evaluate the effectiveness and safety of the TNF-alpha antibody infliximab in the treatment of patients with rheumatoid arthritis
    Tony, H
    Kneitz, C
    Richter, C
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 272 - 272
  • [42] Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: Results from the IMPACT 2 trial.
    Mease, P
    Kavanaugh, A
    Krueger, GG
    Shergy, W
    Halter, D
    De Vlam, K
    Kirkham, B
    Bala, M
    Beutlers, A
    Guzzo, C
    Zhou, B
    Dooley, L
    Antoni, C
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S616 - S616
  • [43] Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Gerd R. Burmester
    Laura C. Coates
    Stanley B. Cohen
    Yoshiya Tanaka
    Ivana Vranic
    Edward Nagy
    Irina Lazariciu
    All-shine Chen
    Kenneth Kwok
    Lara Fallon
    Cassandra Kinch
    Rheumatology and Therapy, 2024, 11 (1) : 221 - 222
  • [44] Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance
    Harigai, Masayoshi
    Ishiguro, Naoki
    Inokuma, Shigeko
    Mimori, Tsuneyo
    Ryu, Junnosuke
    Takei, Syuji
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Takasaki, Yoshinari
    Yamanaka, Hisashi
    Yoshizawa, Yuri
    Chineni, Ichino
    Nakao, Toru
    Koike, Takao
    MODERN RHEUMATOLOGY, 2019, 29 (05) : 747 - 755
  • [45] Characterization of Patients with Rheumatoid Arthritis Treated with Rituximab or Tocilizumab in Post-Marketing Patient Registries
    Tatt, Iain D.
    Sarsour, Khaled
    Robinson, Jamie
    Low, Eric
    Napalkov, Pavel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 440 - 441
  • [46] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study
    Kameda, Hideto
    Nishida, Keiichiro
    Nanki, Toshihiro
    Watanabe, Akira
    Oshima, Yukiya
    Momohara, Shigeki
    MODERN RHEUMATOLOGY, 2023, 33 (03) : 460 - 471
  • [47] Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
    Marotte, Hubert
    Mammar, Nadir
    Fautrel, Bruno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    Fleischmann, RM
    Cohen, SB
    Moreland, LW
    Schiff, M
    Mease, PJ
    Smith, DB
    Keenan, G
    Kremer, JM
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1181 - 1190
  • [49] Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study
    Ju, Ji Hyeon
    Sung, Yoon-Kyoung
    Jo, Joo-young
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Lee, Eun Bong
    MODERN RHEUMATOLOGY, 2023, 33 (06) : 1087 - 1096
  • [50] Bone tissue metabolism in rheumatoid arthritis patients treated with infliximab and methotrexate
    Zon-Giebel, A
    Kucharz, E
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 221 - 221
12345